ANKUR
DRUGS AND PHARMA LTD

CDR has approved the Company's restructuring proposal vide its letter dtd. 19th September 2011. The gist of restructuring is given hereunder:

01. Out of total term loans of Rs.164.82 Crores and working capital term loan of Rs.531.31 Crores restructured by CDR Lenders on the cut-off date i.e. 31st December 2010, Rs. 137.12 Crores shall be converted into 0.001% OCCRPS which can be converted in Equity Shares at the end of 18 months at the option of Banks as per SEBI guidelines. If the Banks do not opt for conversion, then the said OCCRPS shall be redeemable on December 31, 2020 at a redemption premium of 8% p.a. on Simple basis.

02. Except for Term Loans of Rs.48.48 Crores (Rate of Interest approx. 8.50% from 1st January 2011 to 31st March 2012) all term loans and working capital term loans shall carry interest @ 2% p.a. from 1st January 2011 to 31st March 2012, thereafter; it would increase gradually to give an average interest yield of 11% p.a.

03. The repayment of Term Loans and Working Capital Term Loan shall be as under.

Repayment as % of Outstanding Amount	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021
	0.00%	0.00%	2.50%	5.00%	10.00%	10.00%	15.00%	15.00%	20.00%	22.50%

04. CDR has also permitted raising of Long Term funds to the extent of Rs.125.00 Crores against first pari-passu charge on company's fixed assets. Against this, the Company shall be raising Rs.60.00 Crores immediately by way of NCD issue.

05. After carving out the WCTL, the Working Capital outstanding would be Rs.64.64 Crores which will carry interest @11.5%p.a. Additional Working Capital requirement shall be met by Factoring / Bills Discounting of Company's receivables which have been permitted under this restructuring proposal.

06. The unsecured loans of Promoters shall be converted into Equity Shares as per SEBI guidelines.

07. Promoters have to bring in additional Rs.15.00 Crores of which 50% has to come up-front and balance 50% within one year from date of L.O.A.